Instapath Inc. aims to enhance biopsy accuracy and efficiency through advanced digital microscopic imaging devices. Their core mission is to improve rapid on-site evaluation (ROSE) of biopsies, reducing the need for repeat procedures and increasing hospital revenue. Instapath's innovative technology addresses the significant issue of inaccurate diagnoses in over 20% of biopsy procedures, benefiting both patients and healthcare providers.
Instapath has made significant strides in the medical imaging market, positively impacting over 7 million Americans who undergo biopsy procedures annually. By reducing the frequency of costly and painful repeat biopsies, Instapath not only improves patient outcomes but also optimizes operating room capacity. Their contributions to the healthcare industry underscore the importance of technological advancements in medical diagnostics.
